$218.23-6.04% · 3M
Moving avg
1W+2.58%
1M-8.13%
3M-4.17%
6M+20.43%
YTD+22.13%
1Y+100.67%
3Y+204.58%
5Y+928.42%
52-week range
$96.0974% of range$260.19
Company health
Value0/6
Growth3/6
Profitability1/6
Health3/6
Dividend0/6
Bull vs bear
Strengths
- Analysts see 22% upside to a $265 target
- Analyst consensus is "Buy"
- Revenue compounding 134% a year
- Net cash on the balance sheet
Risks
- Currently unprofitable
- Burning free cash flow
- Highly leveraged (debt is 2.7x equity)
Key statistics
Valuation
Market cap
$11.23B
Enterprise value
$12.25B
P/E ratio (TTM)
-64.24x
P/S ratio (TTM)
17.41x
EV/EBITDA
-70.90x
Per share & returns
EPS (TTM)
-$3.68
Dividend yield
0.00%
Beta (1Y)
0.60
30-day change
-8.13%
Trading
Volume (24h)
220.25K
Previous close
$214.66
Shares outstanding
51.46M
About Axsome Therapeutics, Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
AXSM
Axsome Therapeutics, Inc. is a large-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker AXSM.
Frequently asked questions
What is Axsome Therapeutics, Inc.'s market cap?
Axsome Therapeutics, Inc. (AXSM) has a market capitalization of $11.23B.
What sector is Axsome Therapeutics, Inc. in?
Axsome Therapeutics, Inc. operates in the Healthcare sector, Biotechnology industry.
What exchange does AXSM trade on?
AXSM trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,220.02-0.02%
$1.15T cap
Johnson & JohnsonJNJ
$261.21+0.13%
$629.49B cap
AbbVie Inc.ABBV
$250.31+0.62%
$442.25B cap
UnitedHealth Group IncorporatedUNH
$403.33-0.56%
$366.28B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$355.30B cap
Merck & Co., Inc.MRK
$134.58+1.25%
$332.39B cap
Novartis AGSWX: NOVN
CHF 123.96-0.19%
$290.28B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.27B cap